MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease
Status:
Not yet recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
This study is a phase 2a randomized double-blind, placebo-controlled, study, in
mild-to-moderate Alzheimer's disease, of the oral investigational drug MW150, a p38alphaMAPK
kinase inhibitor. The primary goals of this study are to investigate the safety and
tolerability, and drug movements in the body. The secondary goals of the study are to
investigate the effects of the drug on cognitive performance, activities of daily living, and
behavior, and the biological effects of the drug on blood biomarkers.
Phase:
Phase 2
Details
Lead Sponsor:
Neurokine Therapeutics
Collaborators:
Columbia University National Institute on Aging (NIA)